Small molecule · developed by Kymera Therapeutics
KT-474 (also known as SAR-444656) is an oral tablet studied in healthy volunteers, atopic dermatitis and hidradenitis suppurativa.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04772885 | Phase 1 | Healthy Volunteer | Completed | KYMR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atopic DermatitisHealthy VolunteerHidradenitis Suppurativa
Updated Oct 18, 2026. Something wrong or missing? Report it on the KYMR page.
See KYMR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KYMR catalysts and pipeline →